SLC5A2 and Insulin resistance: In view of the broad biological effects, including lowering of serum levels of glucose and blood pressure, reducing plasma volume, suppressing inflammation and oxidative stress, improving insulin resistance and increasing energy metabolism, SGLT2 inhibitors can maintain cardiac hemodynamic and electrophysiological stability, alleviate abnormal hypertrophy and remodeling, and improve myocardial systolic and diastolic function which are, theoretically, beneficial to patients with HFpEF.